Clinical Trial

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 23, 2025 (before its estimated January 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an open label, Phase 1, dose escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab in patients with immune checkpoint inhibitor refractory non-small cell lung cancer.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-11-05; most recent amendment 2025-12-19.
Status change: Recruiting → Active, Not Recruiting 2025-12-19
Status change: Not Yet Recruiting → Recruiting 2024-03-21
Trial Details
NCT Number NCT06125197
Lead Sponsor TILT Biotherapeutics Ltd.
Collaborators: Merck Sharp & Dohme LLC
Conditions Lung Cancer
Enrollment 22 participants
Start Date 2024-07-23
Primary Completion 2026-01-30 (estimated)
Study Completion 2026-05-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-23